Products with Nephrotoxic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN1281 | Norcantharidin |
| Norcantharidin has been used to treat human cancers in China since 1984, it inhibits the canonical Wnt signal pathway in NSCLC, by activating WIF-1 via promoter demethylation; it also enhances TIMP‑2 antitumor and anti‑vasculogenic mimicry activities in GBCs through downregulating MMP‑2 and MT1‑MMP. Norcantharidin is a protein phosphatase type-2A inhibitor, which has less nephrotoxic and phlogogenic side-effects, it can inhibit both DNA synthesis and granulocyte-macrophage colony-forming cells (GM-CFC)growth and impaire the neogenesis of chromatin material and nuclear membrane during the M/G1 phase transition in K-562 cells. | |
| BCN2160 | Sodium barbital |
| 1. Sodium barbital was used as a model non-genotoxic renal carcinogen to test whether a concentration that increased renal tubular proliferation without severe nephrotoxicity would enhance tumor induction in a hereditary tumor model. 2. Sodium barbital causes progression to the stage of spontaneous renal lesions in Tsc2 mutant rats but do not increase their overall number. 3. Sodium barbital is a depressant of the central nervous system, has sedative/hypnotic effects. 4. Sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), it might compete with both creatine and ATP, but mainly with creatine, to inhibit the activity of CK. 5. Sodium barbital is a tumour promoter, it can shorten the otherwise long latency between exposure to toxin and tumourigenesis. | |
| BCN2359 | Telocinobufagin |
| Telocinobufagin is a novel endogenous digitalis, it shows a reversible local anesthetic action, similar to BUPI, however, without cardiac toxicity in vitro. Telocinobufagin has antimicrobial, potential immune system regulatory effects, it could be developed as a novel immunotherapeutic agent to treat and other immune-mediated diseases, and it may become a new immunomodulatory agent in many regions. | |
